Revolutionary weight-loss injections like Wegovy and Ozempic have been shown to significantly reduce the risk of several common and deadly cancers, according to a major study. Originally developed for diabetes management, these drugs helped obese patients lower their chances of developing cancers such as breast, bowel, pancreatic, and ovarian by nearly 20%.
Additionally, U.S. researchers found that patients using these weekly injections were half as likely to die over a 15-year period compared to obese patients not on the medication. Experts attribute this to the drugs, known as GLP-1 agonists, which help protect against cancers linked to obesity, including thyroid, kidney, and liver cancers. Obesity, second only to smoking, is a major cause of cancer in the UK, accounting for about one in 20 new cases annually.
